Applies to the following strengths: 35 mg; 70 mg; 40 mg; 5 mg; 10 mg; 70 mg/75 mL Usual Adult Dose for: Osteoporosis Prevention of Osteoporosis Paget's Disease Additional dosage information: Renal Dose Adjustments Liver Dose
Fosamax, Binosto (alendronate) dosing, indications, interactions, adverse effects, and more Limitation of Use Optimal duration of use not determined; for patients at low-risk for
FDA-Approved Indications Alendronate is approved by the U
Frequency of providing care for patients with osteoporosis and impaired renal function programs
16 All laboratory values were within normal limits 3 days
Renal impairment was not even an exclusion criterion for some other studies [8, 9]
In adult subjects with moderate to severe renal impairment or endstage renal disease (ESRD) - (creatinine clearance <60 mL/min), the exposure to teduglutide increased with
Furosemide is a loop diuretic that has been in use for decades
Alendronate sodium is not recommended for patients with creatinine clearance less than 35 mL/min due to lack of
No dosage adjustment is necessary for patients with creatinine clearance 35 to 60 mL/min
No dosage
4 An August 2011 update to the United States labeling for No dosage adjustment is necessary for patients with creatinine clearance 35 to 60 mL/min
• Renal injury uncommon at conventional dosing and frequency intervals (29 with mild or moderate renal impairment – CG CrCl 30–80 ml/min) demonstrated that patients with and without CKD had a reduction in the mineralising surface which was greater in the risedronate group
Alendronate prescription and dosage sizes information for physicians and healthcare professionals
Following a single 10 mg intravenous dose, the renal clearance of alendronate was 71 mL/min (64, 78; 90% confidence interval [CI]), and systemic clearance did not exceed 200 mL/min
People with chronic kidney disease (CKD) are at high risk of bone fractures
Bisphosphonates inhibit bone resorption with relatively few side effects
Some patient factors also influence the decision to adjust drug doses, such as the degree of renal disease and patient size
Renal impairment
Severe renal dysfunction (CrCl less than 30 mL/min): Limited existing data
We hypothesized that, with decreasing renal function, alendronate treatment would result in greater increases in BMD and greater decreases in fractures and that the frequency of adverse events would be increased
No adjustment recommended; use caution in severe renal impairment as there is a greater risk for hypocalcemia